Tumor cell invasion and resistance to therapy are the most intractable biological characteristics of cancer and, therefore, the most challenging for current cancer research and treatment paradigms. Refractory cancers, including pancreatic cancer and glioblastoma, show an inextricable association between the highly invasive behavior of tumor cells and their resistance to chemotherapy, radiotherapy and targeted therapies. These aggressive properties of cancer share distinct cellular pathways that are connected to each other by several molecular hubs. There is increasing evidence to show that glycogen synthase kinase (GSK)-3b is aberrantly activated in various cancer types and this has emerged as a potential therapeutic target. In many but not all cancer types, aberrant GSK3b sustains the survival, immortalization, proliferation and invasion of tumor cells, while also rendering them insensitive or resistant to chemotherapeutic agents and radiation. Here we review studies that describe associations between therapeutic stimuli/resistance and the induction of pro-invasive phenotypes in various cancer types. Such cancers are largely responsive to treatment that targets GSK3b. This review focuses on the role of GSK3b as a molecular hub that connects pathways responsible for tumor invasion and resistance to therapy, thus highlighting its potential as a major cancer therapeutic target. We also discuss the putative involvement of GSK3b in determining tumor cell stemness that underpins both tumor invasion and therapy resistance, leading to intractable and refractory cancer with dismal patient outcomes.
O ne of the well-recognized but still poorly understood characteristics of cancer is its ability to adapt and survive in a harsh microenvironment. Tumor cells survive the hypoxic and starved conditions by changing their morphological and biological properties and by interacting with tumor-associated stromal components. (1) Another striking characteristic of cancers is their ability to invade host organs and to resist therapeutic insults, thus limiting the success of curative tumor resection and leading to tumor metastasis and therapy failure. These pathological behaviors of cancer are associated with acquisition of the hallmark biological traits of cancer. (2) (3) (4) Despite recent advances in cancer treatments, the existence of unresectable and recurrent cancers that share the persistent capacity for invasion, metastasis and therapy resistance remains a challenge for current medical therapies. (5, 6) Although our knowledge of the molecular and biological mechanisms by which cancer evolves to the refractory stage is increasing, (2) few strategies have been established to attenuate the ability of tumors to invade or to prevent the failure of therapy.
Modern options for cancer treatment consist of surgery, cytotoxic or cytostatic chemotherapeutics, radiation, moleculartargeted and immunomodulating agents, and their multidisciplinary combination. (7, 8) These treatments aim primarily to reduce tumor cell survival and proliferation, but not to eliminate invasive ability or resistance to therapy. Therefore, understanding the pathways by which cancer cells acquire both invasive and therapy-resistant phenotypes is critical for the development of more efficient therapeutic strategies against refractory cancers and, therefore, improvements in patient survival. Apart from the known mediators of invasion and therapy resistance [reviewed in Alexander and Friedl (9) ], one emerging candidate is glycogen synthase kinase (GSK)-3b. This molecule has been extensively implicated in critical cell biology processes and has causal roles in common diseases including glucose intolerance, neurodegenerative disorders and cancer. (10) (11) (12) Here we review previous studies that have reported on the association between therapeutic stimuli/resistance and induction of pro-invasive phenotypes in various cancer types. Many of these cancers have proven to be responsive to experimental treatment which targets GSK3b. This review focuses on the role of GSK3b as a molecular hub that connects pathways responsible for tumor invasion and resistance to therapy, thus highlighting this kinase as a promising multipurpose cancer therapeutic target. It also discusses a putative role for GSK3b in sustaining the tumor cell "stemness" that is central to both tumor invasion and therapy resistance, thereby leading to intractable cancer and resulting in treatment failure. (13) (14) (15) Invasion and therapy resistance co-segregate in refractory cancer High invasiveness and resistance to therapy are common biological and clinical characteristics of refractory cancer that represent major challenges for research and treatment. The mechanisms involved in tumor invasion include cell motility and migration, degradation of the extracellular matrix and interaction with stromal and inflammatory cells. These are orchestrated in a way that enables the tumor to invade the host organ and often beyond. (3, 4) An early morphological and functional change for tumor cells of epithelial origin to acquire a proinvasive phenotype is epithelial to mesenchymal transition (EMT), altering cell behavior to resemble a mesenchymal type. (16, 17) The major modes by which cancers evade the effect of anti-cancer drugs include intrinsic (or constitutive) resistance and acquired resistance. Constitutive resistance to therapy may be due to mutational activation of signaling for cell survival, cytoprotective alterations in the cell cycle and in DNA repair ability, differences in the efficiency of drug uptake and efflux by cancer cells, and insufficient drug delivery [reviewed in Alexander and Friedl (9) ]. Acquired resistance to chemotherapeutic and molecular-targeted agents involves distinct mechanisms, including genetic alterations to the drug targets, activation of surrogate prosurvival pathways, and interactions between tumor cells and components of the tumor environment [reviewed in Holohan et al. (5) , Ramos and Bentires-Alj (6) and Alexander and Friedl (9) ]. Intra-tumor heterogeneity emerges in many tumors and often underlies their resistance to therapeutic agents. (18, 19) The processes of tumor invasion and therapy resistance and their underlying mechanisms are often investigated as independent pathological events in cancer. However, recent studies (shown in Table 1 ) have demonstrated that tumor cells acquire morphological and functional proinvasive phenotypes with the ability to migrate and invade following the development of resistance to anti-cancer therapeutics (Suppl. References [SR] 1-24) (Data S1).
(SR1-24) The therapeutic modalities included conventional chemotherapeutic agents , different types of radiation therapy as well as bioactive compounds targeting epidermal growth factor (EGF) receptor and vascular endothelial growth factor (VEGF).
(SR21-24) These studies indicate the therapeutic insult and/or resistance elicits proinvasive phenotypes and evokes the invasive capability of tumor cells in a broad spectrum of cancer types, including breast, colorectal, pancreatic, ovarian and prostate cancers, as well as rare intractable tumors (e.g. glioblastoma and osteosarcoma). A large number of preclinical studies have demonstrated that all available cancer treatments, including surgery, facilitate metastatic tumor spread. Such treatment often results in therapeutic benefit, but occasionally also results in resistance, leading to the paradoxical concept of "treatment-induced metastasis" [reviewed in Ebos (20) ]. These experimental and preclinical studies suggest that the invasive behavior of cancer cells and their acquired resistance to therapy may not be separate pathological properties and could, instead, represent interconnected processes [reviewed in Alexander and Friedl (9) ].
Regardless of the tumor type and therapeutic agent, the proposed mechanisms for invasion and resistance are attributable to molecular pathways that participate in tumor cell survival, transition to mesenchymal (EMT) and cancer stem cell (CSC) phenotypes, migration and invasion with extracellular matrix degradation, and drug efflux ( Table 1 ). The reported molecules that mediate and interconnect these pathways include growth and transcription factors, chemokines, RAS and Rho family members (e.g. Ras, Rac1) and cell-matrix adhesion molecules (e.g. integrin family and focal adhesion kinase [FAK]) ( Table 1) . (9) Bevacizumab is a humanized monoclonal antibody to VEGF used clinically as an anti-angiogenic agent. Acquired resistance to bevacizumab leads to enhanced tumor cell invasion due to the metabolic shift to glycolysis and degradation and remodeling of tumor stromal tissues.
(SR21- 24) A better understanding of the biological mechanisms underlying the tight association between tumor invasion and therapy resistance should provide a solid rationale for the development of innovative cancer treatments. (9) Aberrant GSK3b in cancer GSK3 is a family of serine/threonine protein kinases comprising two highly conserved isoforms, GSK3a and GSK3b, that show approximately 85% overall homology and 98% homology in their kinase domains. GSK3 is constitutively active in normal cells and its activity is regulated by the differential phosphorylation at serine (S) residues 21 (pGSK3a S21 ) and 9 (pGSK3b S9 ) (both inactive forms), and tyrosine (Y) residues 279 (pGSK3a Y279 ) and 216 (pGSK3b Y216 ) (both active forms) (Fig. 1a,b ). GSK3 regulates a diverse array of physiological cellular functions via the phosphorylation of and interaction with various proteins (Fig. 1c) . Although the two GSK3 isoforms share many substrates, they are not functionally identical and show some differences in their substrate specificity [reviewed in Beurel et al. (10) ]. Negative regulation of GSK3 activity is desirable to maintain physiological cellular functions. A growing number of studies have demonstrated that deregulated GSK3 activity contributes to the pathogenesis and progression of various diseases, including glucose intolerance, neurodegenerative disorders, and chronic inflammatory and immunological diseases. (10, 21) This points to GSK3 being an attractive and druggable target for a broad spectrum of diseases. (22) Consequently, many GSK3 inhibitor compounds have been developed in academic and pharmaceutical institutes over recent years. Some are reported to inhibit both the a and b isoforms with different affinities, while others are specific for GSK3b (reviewed in SR25,26). Among the latter compounds, it was reported that AR-A014418 does not inhibit the activity of 26 closely related kinases and is, therefore, considered to be highly specific for GSK3b.
Of the two GSK3 isoforms, most studies in the field of oncology have focused on GSK3b. This is partly because of the functional redundancy of the two isoforms in regulating the canonical Wnt/b-catenin pathway, responsible for generating the most prevalent oncogenic signaling. (23, 24) Based on its known effects on several proto-oncoproteins (e.g. b-catenin, cyclin D1 and c-Myc), cell cycle regulators (e.g. p27 Kip1 ) and mediators of EMT (e.g. snail) (Fig. 1c) , it has long been recognized that GSK3b suppresses tumor development [reviewed in Clevers and Nusse, (24) Jope et al., (25) Luo (26) and McCubrey et al. (27) ], as discussed later (Table S1 ).
(SR30-58) Paradoxically, our earlier studies found increased expression and deregulated activity of GSK3b due to changes in the differential Suppression of tumor cell survival and proliferation by inhibition of hTERT/ telomerase and promoting p53-dependent apoptosis (28) (29) (30) 32, 33) and invasion by downregulation of WAVE2, (68) and enhancing 5-FU effect via PARP1-dependent and AIF-mediated necroptosis (73) Erlotinib EMT induction
Pancreatic cancer Gemcitabine EMT induction with activation of b-catenin and c-Met and acquisition of CSC phenotype
Suppression of tumor cell survival and proliferation (30) by inhibition of NF-jB transcriptional activity, (34, 35) synergistic with gemcitabine by restoration of Rb function (60) and inhibition of TP53INP1-mediated DNA repair, (70) increase in radiosensitivity and suppression of invasion via FAK/Rac1/MMP-2 and CXCR4/MMP-2 pathways Suppression of tumor cell survival and proliferation by eliminating TRAIL resistance, repressing AR activity, (41) (42) (43) (44) phosphorylation of S9 and Y216 residues in gastrointestinal cancers, glioblastoma and osteosarcoma compared to respective normal cells and tissues. (28) (29) (30) (31) These observations suggested that GSK3b could participate in cancer development and progression, despite the general belief that it has tumorsuppressive functions. (25) (26) (27) We and other research groups have shown that inhibition of GSK3b activity with specific pharmacological inhibitors, or inhibition of its expression by RNA interference, can preferentially attenuate the survival and proliferation of tumor cells and induce them to undergo apoptosis. This effect has been observed not only in gastrointestinal and pancreatic cancer cells (28) (29) (30) (32) (33) (34) (35) but also in glioblastoma, (31, 36, 37) (38) and other malignant neoplasms such as gynecological and urogenital cancers, (39) (40) (41) (42) (43) (44) (45) (46) (47) soft tissue sarcomas, (48, 49) hematological malignancies (50, 51) and lung cancers. (52, 53) This accumulating evidence firmly establishes GSK3b as a valuable target in cancer treatment. (11, 12) There has been substantial interest in the molecular mechanisms by which GSK3b favors tumor progression and by which inhibition of its activity or expression attenuates tumor cell survival, immortalization and proliferation. The reported mechanisms for tumor cell survival include the nuclear factor (NF)-jB-mediated prosurvival pathway, (34) (35) (36) 38) tumor cell resistance to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), (41) and failure of the p53-mediated tumor suppressor pathway or of the Rb-mediated cell 
Suppression of tumor cell survival and proliferation by restoring p53/p21 pathway and inhibition of c-Myc, NF-jB and abnormal glycolysis, (31, 36) synergistic with temozolomide and increase in radiosensitivity via Rb-mediated and c-Myc/DMNT3A/MGMT pathways, (31, 69) suppression of invasion (58, 59, 61) by inhibition of FAK/Rac1/JNK pathway (61) and induction of CSC differentiation (37, 77) Sublethal irradiation
Enhanced tumor cell migration and invasion involving avb3 integrin, MMP-2, MMP-9, MT1-MMP, TIMP-2 and BCL-2/BAX rheostat
Ionizing radiation Enhanced tumor cell migration with increased expression of b3 and b1 integrins cycle regulation. (31, 32) Preservation of telomere length by maintaining activity of human telomerase reverse transcriptase (hTERT) and telomerase also immortalizes tumor cells in response to the aberrant activation of GSK3b. (30) Cell proliferation pathways mediated by c-Myc and cyclin D1 sustain tumor cell proliferation that is dependent on GSK3b. (36, 39) In osteosarcoma and rhabdomyosarcoma, the induction of b-catenin signaling, a well-known tumor suppressive mechanism in these cancers, has been linked to decreased cell proliferation following GSK3b inhibition (S. Shimozaki et al., unpublished data). (49) Another recent study reported that mitotic catastrophe caused by disruption of centrosome biodynamics was associated with attenuated tumor cell survival and proliferation following GSK3b inhibition. (54) Importantly, GSK3b has little impact on the cell survival, immortalization and growth of normal cells, where the differential phosphorylation of S9 and Y216 residues functions to fine tune GSK3b activity. (28) (29) (30) (31) 34) The growing body of evidence on the role of aberrant GSK3b in sustaining and promoting cancer cell survival, immortalization and proliferation, together with the differential effects of GSK3b inhibition on cancer and normal cells, underpins the targeting of GSK3b as a novel cancer treatment. (11, 12) GSK3b mediates both the invasive phenotype and therapy resistance in refractory cancer
The dependency of cancer cells on GSK3b for their survival and proliferation has encouraged further studies on whether aberrant GSK3b participates in tumor cell invasion and therapy resistance, the two major determinants of patient outcome. (3) (4) (5) (6) As shown in Table 1 , most tumors that acquire pro-invasive phenotypes as they evade therapy are susceptible to experimental treatment involving inhibition of GSK3b. Here we review what is known about the involvement of GSK3b in tumor invasion and resistance to therapy based on our previous studies in pancreatic cancer and glioblastoma. These are representative of lethal tumors and are characterized by high invasive capacity and resistance to available therapies. (55, 56) GSK3b and cancer invasion. While GSK3b plays pivotal roles in cytoskeletal organization, cell polarity and migration in the physiological processes of organogenesis and wound healing, (57) little is known about its role in cancer cell motility, migration and invasion. Earlier studies showed that lithium chloride and some indirubins, both classical GSK3-inhibiting agents, inhibited the migration and invasion of glioblastoma The kinases indicated in blue phosphorylate GSK3b-S9 resulting in its inactivation, while those indicated in red phosphorylate GSK3b-Y216 resulting in its activation. (c) GSK3b stabilizes/activates (red arrows) and destabilizes/inactivates (blue lines) various transcription factors as well as structural and functional proteins. AP-1, activator protein 1; APC, adenomatous polyposis coli; BAX, BCL2-associated X protein; BCL, B-cell lymphoma; C, C-terminal of protein; C/EBP, CCAAT (cytosine-cytosine-adenosine-adenosine-thymidine)-enhancer-binding protein; cdc25A, cell division cycle 25 homolog A; CREB, cAMP (cyclic adenosine monophosphate) response element binding protein; CRMP2, collapsin response mediator protein 2; eIF2B, eukaryotic initiation factor 2B; FAK, focal adhesion kinase; FGD-1/3, FYVE RhoGEF (guanine nucleotide exchange factor) and PH domain-containing protein 1/3; FKHR, forkhead in rhabdomyosarcoma; Gly, glycine; GR, glucocorticoid receptor; GS, glycogen synthase; GSK3b, glycogen synthase kinase 3b; HIF-1a, hypoxia inducible factor-1a; HSF-1, heat shock transcription factor-1; ILK, integrin-linked kinase; IPF1/PDX1, insulin promoter factor 1/pancreatic and duodenal homeobox 1; IRS1, insulin receptor substrate 1; LRP5/6, lipoprotein receptor-related protein 5/6; MafA, musculoaponeurotic fibrosarcoma oncogene homolog A; MAP1B/2C, microtubule associated protein 1B/2C; Mcl1, myeloid cell leukemia 1; mCRY2, mouse cryptochrom 2; MDM2, mouse double minute 2 homolog; MEK, MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-regulated kinase) kinase; MITF, microphthalmia-associated transcription factor; MLK3, mixed lineage kinase 3; N, N-terminal of protein; NAC-a, nascent polypeptide-associated complex subunit-a; NF-AT, nuclear factor of activated Tcells; NF-jB, nuclear factor-jB; Nrf2, nuclear factor erythroid 2-related factor 2; p130RB, p130 retinoblastoma; p21CIP1, p21 CDK (cyclin-dependent kinase)-interacting protein 1; p90RSK, p90 ribosomal protein S6 kinase; PDH, pyruvate dehydrogenase; PKA, protein kinase A; PKC, protein kinase C; PP2A, protein phosphatase 2A; PPAR, peroxisome proliferator-activated receptor; PTEN, phosphatase and tensin homolog; Pyk-2, proline-rich tyrosine kinase 2; RAR, retinoic acid receptor; Red1, RNA-editing deaminase 1; S, serine; SRC-3, steroid receptor coactivator cells, but the mechanism underlying this effect was not clear. (58, 59) Subsequently, we demonstrated that inhibition of GSK3b by a specific pharmacological inhibitor and by RNA interference decreases the capacity for migration and invasion of pancreatic cancer and glioblastoma cells and of their tumors in animal models. (60, 61) Morphologically, these effects were associated with reduced formation of lamellipodia and invadopodia, the horizontal and vertical cellular surface microarchitectures, respectively, that drive cell migration, stromal degradation and invasion. (62, 63) Inhibition of GSK3b disrupted the functional subcellular colocalization of Rac1 (64) and cortactin (63) with the cytoskeletal molecule F-actin in lamellipodia and invadopodia, respectively. These changes in the pro-invasive phenotype of tumor cells following GSK3b inhibition coincide with the suppression of molecular pathways mediated by focal adhesion kinase (FAK), (65) guanine nucleotide exchange factors (GEF)/Rac1 (64, 66) and c-Jun N-terminal kinase (JNK). This results in decreased expression of matrix metalloproteinase (MMP)-2 and membrane type (MT) 1-MMP. Our observations therefore suggest that GSK3b sustains tumor invasion via the promotion of morphological and functional pro-invasive cellular phenotypes and that the molecular axis involves FAK, GEFs/Rac1 and JNK (Fig. 2) . (60, 61) Subsequent to our studies, (60, 61) other workers have reported the proinvasive effect of GSK3b in pancreatic, colorectal and breast cancer cells in association with modulation of cytoskeletal organization and cytokine-mediated matrix degradation. (67, 68) . These studies highlight the pivotal role of GSK3b in tumor invasion and probably also in metastatic spread.
GSK3b and cancer therapy resistance. The combination of multiple agents having different targets and mechanisms of actions is important in the treatment of cancer in order to optimize the therapeutic effects and minimize the adverse effects. This is particularly relevant for the treatment of refractory cancer, and, hence, molecular-targeted therapy is often combined with conventional chemotherapeutics and/or radiation therapy, as well as with other targeted agents. (7, 8) As discussed above, accumulating evidence on the effects of GSK3b inhibition against cancer cell survival and proliferation has led us to address whether this could be used in combination with chemotherapy and irradiation.
The standard treatment modalities prescribed are often ineffective in patients with refractory tumors such as pancreatic cancer and glioblastoma. (55, 56) We have shown that administration of a GSK3b-specific pharmacological inhibitor (e.g. AR-A014418) (SR29) at a dose below that which results in a therapeutic effect when given on its own can significantly enhance the cytotoxic effects of temozolomide and gemcitabine. (31, 60, 69, 70) These are the standard chemotherapeutic agents prescribed for patients with glioblastoma and pancreatic cancer, respectively. (55, 56) Low-dose GSK3b inhibitor given in combination with chemotherapeutic agents had additive and synergistic effects. Investigation of the underlying molecular mechanism is crucial to justify treatment combinations of GSK3b inhibitor with other anti-cancer therapeutics (Fig. 3) . In glioblastoma, the combined effect was attributed to modulation of the mouse double minute (Mdm)2/p53 and c-Myc-mediated pathways resulting in epigenetic silencing of O 6 -methylguanine DNA methyltransferase (MGMT), a clinically proven biomarker of temozolomide efficacy (56) in tumor cells (Fig. 3b) . (31, 69) In pancreatic cancer, inhibition of tumor GSK3b activity decreased cyclin D1/cyclin-dependent kinase (CDK)4/6 complex-dependent phosphorylation of Rb tumor suppressor protein. (60) One of the important functions of Rb is to bind the oncogenic transcription factor E2F1 and inhibit its transcriptional activity. (71, 72) GSK3b may, therefore, sensitize pancreatic cancer to gemcitabine by downregulating the expression of ribonucleotide reductase, a well-known pharmacological biomarker of gemcitabine (55) that is regulated by the Rb/E2F pathway (Fig. 3a) . (71, 72) In addition to modulation of this pathway, we found that downregulation of the TP53INP1 gene (encoding tumor p53-induced-nuclear-protein 1) involved in DNA repair is associated with the chemosensitizing effect of GSK3b inhibitor. (70) The GSK3b inhibitor used in these studies also sensitized both pancreatic cancer and glioblastoma to ionizing radiation. (31, 60) This radio-sensitizing effect may depend on the restoration of Rb function following GSK3b inhibition, resulting in the inability of E2F1 to induce the transcription of thymidylate synthase and thymidine kinase (Fig. 3a) .
Other recent studies have also reported that GSK3b inhibition allows therapy-resistant colon and pancreatic cancer cells to become susceptible to 5-fluorouracil (5-FU), (73) and renal cell carcinoma cells to become susceptible to a synthetic multikinase inhibitor (sorafenib) that targets growth signaling and angiogenesis. (74) Together, these studies suggest that GSK3b participates in multiple molecular pathways used by various cancer types to evade chemotherapy, radiotherapy and targeted therapies.
Collectively, a growing body of experimental evidence supports the notion that GSK3b is a molecular "hub" that mediates and connects various pathways responsible for tumor invasion and resistance to therapy. Together with the role of GSK3b in promoting tumor cell survival and proliferation and its differential functions between tumor and normal cells [reviewed in Miyashita et al. (11) and McCubrey et al. (12) ], this evidence reinforces the promise of novel cancer therapeutic strategies that target GSK3b.
Future perspectives
Targeting of the biological pathways that link tumor invasion and therapy resistance is clearly an attractive prospect for the development of innovative cancer treatments. Another important challenge is to understand the biology of cancer initiating or stem-like cells (CSC) so that "stemness" phenotypes can also be targeted. Based on the clonal evolution model of tumorigenesis and on the normal stem cell concept, CSC are conceptually defined as a population of tumor cells with selfrenewing and pluripotent capacity. (13) CSC have been identified in a wide range of hematopoietic malignancies and solid tumors and are assumed to be progenitors of the entire neoplastic cell population. One of the most striking characteristics of CSC is their influence on tumor cell plasticity, intra-tumor heterogeneity, invasion and metastasis, therapy resistance and tumor relapse after surgery and adjuvant treatment. (14, 75) Eradication of CSC is, therefore, of paramount clinical importance for combatting refractory cancer. (15, 76) GSK3b has pivotal functions in normal cell biology (10, 21, 22) and is also central to the processes of cancer cell survival, proliferation, invasion and therapy resistance, as discussed above. A number of studies have reported that CSC phenotypes share unique molecular pathways and tumor-environment interactions that are also associated with tumor invasion and therapy resistance. (14, 75) This leads us to propose a working hypothesis whereby GSK3b underlies the basal mechanism for sustaining the CSC phenotype (Fig. 4) . Recent studies have shown that GSK3b negatively controls the differentiation of malignant glioma cells, (77) and that GSK3b inhibition results in depletion of cancer stem-like or progenitor-like cells and attenuation of metastatic spread in prostate cancer. (78) Consistent with the physiological roles of GSK3b in negatively regulating canonical Wnt/b-catenin and hedgehog signaling, (10, 23, 24) inhibition of GSK3b is a prerequisite for the maintenance of "stemness" phenotypes in embryonic and hematopoietic stem cells. (79, 80) Therefore, future work should aim to understand the influence of GSK3b on both tumor and normal stem cell phenotypes. This knowledge can be applied for the development of novel cancer treatments that target GSK3b.
One of the concerns about targeting GSK3b for cancer treatment is that its inhibition may promote the progression of existing tumors [reviewed in Takahashi-Yanaga (22) , Jope et al., (25) Luo (26) and McCubrey et al. (27) ]. A number of studies have focused on the putative tumor suppressive role of GSK3b (Table S1 ).
(SR30-58) Many of these report inactivation or activation of GSK3b as a mediating event in pathways leading to tumor progression or suppression, respectively. An inverse association between tumor expression of GSK3b (either total or active form pGSK3b Y216 ) and the survival of cancer patients has been reported. (SR33, 36, 37) Other studies found causal links between pharmacological GSK3b inhibition and/or depletion of GSK3b expression (e.g. gene knockout and RNA interference) or activity (e.g. recombinant kinase-dead or constitutively active mutant form) and tumor cell survival, proliferation (SR40, 52) and susceptibility to cancer therapies.
(SR32, 34, 58) GSK3b inhibition strategies and the development of GSK3b-targeted agents therefore require careful evaluation to determine whether the tumor promoting function of GSK3b is counteracted by its putative tumor suppressor function in different cancer types. The development and administration of GSK3b inhibitors for the treatment of chronic diseases, including diabetes mellitus, neurodegenerative disorders and cancer, requires serious awareness of the safety issues. A major concern is whether and how GSK3b can be targeted to treat disease, because its systemic inhibition may lead to unwanted effects by disrupting multiple biological pathways (Fig. 1c) . Most notably, longterm inhibition of GSK3b may initiate tumorigenesis due to its role in suppressing proto-oncogenic pathways, in particular that are mediated by b-catenin [reviewed in TakahashiYanaga (22) , Jope et al., (25) Luo (26) and McCubrey et al. (27) ]. A previous study showed that genetic deletion of GSK3b in mammary epithelial cells resulted in b-catenin activation and induced intraepithelial neoplasia that progressed to the development of adenosquamous carcinoma.
(SR51) Moreover, overexpression of wild-type and constitutively active mutant GSK3b in 12-O-tetradecanoylpholbor-13-acetate (TPA)-mediated, transformation-resistant mouse epidermal cells suppressed EGF-mediated and TPA-mediated anchorage-independent growth in soft agar and tumorigenicity in rodents (Table S1 ).
(SR56) However, there is currently no direct evidence to support tumor development in vivo following treatment with a GSK3b inhibitor [reviewed in Miyashita et al. (11) and SR27]. As discussed in previous studies that report cancer therapeutic effects of GSK3b inhibition (Table 1) , none of the available experimental GSK3b inhibitors induces neoplastic transformation of non-neoplastic (normal) cells or tumor development in experimental animal models [reviewed in Miyashita et al. (11) and SR27]. Long-term prescription of lithium, the only GSK3b inhibitor approved for the treatment of bipolar disorder since the 1950s, has not been associated with an increased risk of cancer or death from cancer.
(SR59) Post-translational regulation of GSK3b activity via the phosphorylation of S9 and Y216 (pGSK3b S9 versus pGSK3b Y216 ) (Fig. 1b ) in response to various stimuli could partly underlie a mechanism that protects normal cells from the detrimental effects of GSK3b inhibition.
Despite the concerns outlined above, clinical trials for neurodegenerative diseases and cancer have tested some seed pharmacological GSK3(b) inhibitor compounds and also approved medicines with the ability to inhibit GSK3b activity (Table S2 ). The former trials include AZD-1080 (AstraZeneca) for the treatment of Alzheimer's disease (phase I), and NP031112 (tideglusive; Noscira SA) for the treatment of progressive supranuclear palsy (NCT01049399: phase IIb) (SR60, 61) and of Alzheimer's disease (NCT01350362: phase II).
(SR62, 63) Clinical trials for cancer treatment have used LY2090314 (Eli Lilly) alone for acute leukemia (NCT01214603: phase II), and the same compound in combination: (i) with gemcitabine, the combined folate, 5-FU and oxaliplatin (FOLFOX) regimen or the combined gemcitabine and nab-paclitaxel regimen for metastatic pancreatic cancer (NCT01632306: phase I/II); and (ii) with pemetrexed and carboplatin for advanced or metastatic solid cancer (NCT01287520: phase I).
(SR64,65) Our group is undertaking the phase I/II clinical trials by repurposing approved GSK3b-inhibiting medicines (combined cimetidine, lithium, olanzapine and valproate regimen) in combination with gemcitabine for advanced pancreatic cancer (UMIN000005095) and with temozolomide for recurrent glioblastoma (UMIN000005111) (T. Furuta, H. Sabit, D. Yu, K. Miyashita, M. Kinoshita, M. Kinoshita, Y. Hayashi, Y. Hayashi, T. Minamoto, M. Nakada, unpublished data, 2016).
Currently, information regarding the side effects of GSK3b inhibitors is limited because the clinical trials have evaluated only a small number of seed compounds and also because lithium chloride is the only currently approved inhibitor for clinical use. It is, therefore, difficult to predict what serious adverse events, if any, will occur in patients treated with GSK3b inhibitors. The extent of GSK3b inhibition and the differential effects between normal and diseased cells/tissues (therapeutic window) are critical determining factors for therapeutic efficacy and undesirable side effects. It is clear that GSK3b activity is deregulated in various pathological conditions, including many, but not all, cancer types (Table 1) . (10) (11) (12) 22, (25) (26) (27) Identifying the range of GSK3b inhibition that is efficient for treatment of disease but which results in minimal detrimental effects to normal tissues and organs will be important for the clinical application of GSK3b inhibitors. Numerous studies have shown that, in addition to differential phosphorylation at S9 and Y216 residues (Fig. 1a,b) , the subcellular localization of GSK3b together with various upstream pathways can regulate the expression and activity of this kinase [reviewed in Beurel et al. (10) and Takahashi-Yanaga (22) ]. New classes of GSK3b inhibitors that spatially and temporally control the expression and activity of GSK3b may therefore be required to reduce the risk of adverse events such as carcinogenesis that may be associated with long-term GSK3b inhibition.
